Drugs / Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06043388 | Sep → Dec 2023 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06043388 ↗ |
| Modality | Vaccine | “recombinant novel coronavirus protein vaccine” NCT06043388 ↗ |
| Route | Intramuscular | “Intramuscular injection into the deltoid muscle of the upper arm” NCT06043388 ↗ |